1800 202 8726
Targeted therapy

Antiangiogenic Drugs (VEGF Inhibitors): — How Starving a Tumour Works

VEGF inhibitors work by blocking a protein that tells the body to grow new blood vessels into a tumour. Cutting off that supply is the goal — and it is used in kidney, colorectal, liver, lung, thyroid, and gastric cancers, either alone or alongside chemotherapy or immunotherapy.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026

  • The target is the blood supply — Tumours cannot grow beyond a small size without recruiting new blood vessels. VEGF inhibitors block the signal that starts that process.
  • Two types of drug — Monoclonal antibodies bind to the VEGF protein directly. Tyrosine kinase inhibitors (TKIs) block the receptor on blood vessel cells that VEGF would normally switch on.
  • Used across many cancers — NCCN and ASCO guidance includes antiangiogenic drugs in standard treatment pathways for kidney, colorectal, liver, lung, thyroid, and gastric cancers, among others.
  • Different side effects from chemotherapy — Hair loss is uncommon. High blood pressure and slower wound healing are more typical of this drug class.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Talk to a medical oncologist

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Reviewed by a senior medical oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

VEGF inhibitors block a protein called vascular endothelial growth factor, which tumours use to grow new blood vessels. Without that supply, the tumour is starved of nutrients. These drugs are used in kidney, colorectal, liver, lung, thyroid, and gastric cancers, among others, and are named in NCCN and ASCO treatment guidelines for each.

How do VEGF inhibitors cut off a tumour's blood supply?

Every tumour beyond a small size needs a blood supply to survive. To build one, tumour cells release a protein called VEGF — vascular endothelial growth factor — which signals nearby blood vessel cells to grow towards the tumour and feed it.

VEGF inhibitors interrupt that signal. Some, called monoclonal antibodies, bind to the VEGF protein in the bloodstream before it can reach its target. Others, called tyrosine kinase inhibitors or TKIs, block the receptor on blood vessel cells that VEGF would normally switch on.

Without a new blood supply, the tumour is starved of nutrients and oxygen. This does not destroy the tumour directly — it slows or constrains growth, which is why these drugs are most often used alongside other treatments rather than alone.

Which cancers are VEGF inhibitors used for?

NCCN and ASCO guidance includes antiangiogenic drugs in standard treatment pathways for several cancers. The specific drug is chosen based on cancer type, prior treatment history, and kidney and liver function — not on VEGF testing of the tumour tissue.

In kidney cancer (renal cell carcinoma): sunitinib, pazopanib, axitinib, and cabozantinib are established options across different lines of treatment. In colorectal cancer: bevacizumab is used alongside chemotherapy. In liver cancer (hepatocellular carcinoma): sorafenib, lenvatinib, and regorafenib are used at different stages of disease.

In non-small cell lung cancer: bevacizumab is used in certain subtypes alongside chemotherapy. In thyroid cancer: lenvatinib, sorafenib, and cabozantinib are used when disease no longer responds to radioiodine. In gastric cancer: ramucirumab is an established second-line option per ESMO and ASCO guidance.

Your oncologist selects the right drug for your specific situation. These are prescription medicines given as part of a supervised treatment plan.

Not sure what this means for you?

Share your reports and a senior oncologist will explain your options in plain language — no obligation to start treatment.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What side effects should you watch for?

The side effect profile differs from chemotherapy. Hair loss is uncommon. Instead, effects reflect what VEGF normally does in healthy tissue — it maintains blood vessel walls, supports wound healing, and helps regulate blood pressure.

High blood pressure is the most common side effect across this drug class. ASCO guidance recommends monitoring blood pressure throughout treatment. Tell your team immediately if you develop severe headaches, blurred vision, or chest heaviness — these can signal a blood pressure level that needs urgent attention.

Wound healing slows on antiangiogenic drugs. If you need any procedure or surgery, tell your oncologist before it is scheduled. With TKIs specifically, you may notice redness and soreness on the palms or soles — hand-foot syndrome. Report it early so your team can adjust the dose before it becomes severe.

What does starting antiangiogenic treatment look like?

  1. Baseline checks

    Before you start, your team checks blood pressure, kidney function, liver function, and urine protein. They also review every medicine and supplement you take, because some interact with VEGF inhibitors.

  2. Choosing the drug

    Your oncologist selects the specific drug based on your cancer type, treatment history, and overall health. Monoclonal antibodies are given as intravenous infusions at the clinic. Most TKIs are daily tablets taken at home.

  3. Starting treatment

    Infusions are given as day care — you come in, receive the infusion over a set time, and go home the same day. Tablets are taken as directed, usually at the same time each day, with instructions on whether to take them with food.

  4. Ongoing monitoring

    Blood pressure is checked at visits and you may be asked to monitor it at home. Blood tests look at kidney and liver function. You will be asked about side effects each time you come in.

  5. Response assessment

    After a set number of cycles, a CT scan or other imaging is done to assess whether the tumour is responding. Your oncologist reviews the result and discusses what it means for the next phase of treatment.

Questions families commonly ask

Will I feel as sick as I would on chemotherapy?

The side effect profile is different, not necessarily easier. Nausea and hair loss are uncommon with VEGF inhibitors, but fatigue, high blood pressure, and effects on wound healing are frequent. Some people tolerate these drugs well and continue working; others find fatigue a significant challenge. The specific drug matters — TKIs taken daily as tablets tend to produce more consistent low-grade side effects, while infusion-based antibodies cause reactions around infusion days. Your team can tell you what is most common with the specific drug you are starting.

Can I have surgery while on a VEGF inhibitor?

Antiangiogenic drugs significantly slow wound healing and increase bleeding risk. For any planned surgery, your oncologist will advise pausing treatment in the weeks before and after the procedure. The exact timing depends on which drug you are on and what operation is planned. Do not agree to any procedure — including a dental extraction or endoscopy — without telling both your surgeon and your oncologist, so they can coordinate. If emergency surgery is ever needed, the surgical team should be told immediately that you are on this class of drug.

How do I take the tablet form correctly at home?

Most TKIs are taken once or twice daily, at the same time each day. Some must be taken with food and some without — follow the specific instruction for your drug, because this affects how much reaches your bloodstream. Do not halve, crush, or chew tablets unless your team has confirmed it is safe. If you miss a dose, follow your team's guidance — the rule varies by drug. Never double the next dose to compensate for a missed one. Keep tablets in their original packaging, away from heat and moisture, and out of reach of children.

What happens if my blood pressure goes very high?

High blood pressure on VEGF inhibitors is common and manageable when caught early. Your team may start or adjust blood pressure medicine when treatment begins. The danger is pressure that rises rapidly to very high levels without being detected — this can rarely lead to a hypertensive crisis. Severe headache, visual changes, confusion, or chest pain during treatment are reasons to seek emergency assessment the same day, not to wait for your next appointment. Most people on these drugs are asked to check blood pressure at home and keep a simple log to share at each visit.

Are there foods or supplements I should avoid?

Yes. Grapefruit and grapefruit juice interact with several TKIs by affecting how the drug is broken down in the liver — it can raise drug levels to an unsafe range. Avoid grapefruit entirely while on these medicines unless your team explicitly says it is safe for your specific drug. Herbal supplements, including traditional remedies, can also interact — some affect the same liver enzymes. Tell your oncologist about everything you take, including Ayurvedic or homeopathic preparations, before starting. The purpose of that conversation is to make your treatment as safe as possible.

How long will treatment continue?

VEGF inhibitors are generally continued for as long as the tumour is responding and side effects remain manageable. There is usually no fixed number of cycles set in advance. Your oncologist reassesses with imaging at intervals and discusses the result with you. If the tumour begins to grow despite treatment, or if side effects become unacceptable, the plan will change — to a different drug in the same class, or to a different approach entirely. Some people stay on these drugs for months to years; others change after a few cycles. Your own response is what guides the decision.

Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics

Mutation & Target-Specific Pages

All Targeted Therapy Basics, Testing & Your Cancer Type →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

What exactly is VEGF and why does it matter in cancer?

VEGF stands for vascular endothelial growth factor. It is a protein that signals blood vessel cells to grow — a process called angiogenesis. In normal tissue it helps wounds heal and organs develop. In cancer, tumour cells hijack this process, releasing VEGF to recruit a blood supply that feeds their growth. Without that supply, most tumours cannot grow beyond a small size. VEGF inhibitors are designed to block this recruitment signal at different points in the pathway.

How is an antiangiogenic drug different from chemotherapy?

Chemotherapy targets rapidly dividing cells — which includes cancer cells, but also hair follicles and the gut lining, causing hair loss and nausea. Antiangiogenic drugs target blood vessel formation rather than dividing cells directly, so the side effect profile is different. Hair loss is uncommon. Instead, effects include high blood pressure, slower wound healing, and fatigue. Neither class is inherently milder — the effects are different, and which matters more depends on your specific cancer and overall health.

Which VEGF inhibitor will I be given?

The choice depends on your cancer type, the stage of disease, your prior treatment history, and your kidney and liver function. There is no single best drug across all cancers — NCCN and ASCO guidance lists specific drugs for specific cancers and lines of treatment, and your oncologist follows that evidence. If you want to understand why a particular drug was chosen for your situation, that is a reasonable question to ask at your appointment.

How soon do VEGF inhibitors start working?

There is no reliable sign of activity in the first few days of treatment. The first formal assessment is usually imaging — a CT scan — done after a set number of weeks or cycles. Some people notice changes in symptoms before imaging confirms a response; others notice no change in how they feel even when imaging shows the tumour is stable or shrinking. Neither pattern alone is a reliable guide to whether treatment is working. Wait for the imaging result and discuss it with your oncologist before drawing conclusions.

Can I continue working during treatment?

Many people do, particularly when side effects are well managed. The main challenges are fatigue, which varies widely between individuals and drug types, and the need to monitor blood pressure and attend regular appointments. TKIs taken at home as daily tablets offer more scheduling flexibility than regular infusion visits. Whether you can continue working depends on the demands of your job, how you respond to the specific drug, and whether your employer can accommodate adjustments. Discuss it with your oncologist before making decisions — they can give you a realistic picture of what to expect in the first weeks.

What happens if the treatment stops working?

If imaging shows the tumour growing despite treatment, your oncologist will discuss the available options. For several cancers there are second- and third-line VEGF inhibitors or other drug classes used after the first treatment stops working — in kidney cancer, for example, NCCN guidance lists multiple sequential options. Whether switching to another drug in the same class makes sense, or whether a different approach is better, depends on your cancer type, your overall health, and the evidence for your specific situation. Stopping one treatment does not mean running out of options, and your oncologist should explain what is available and what each is realistically expected to achieve.

Call now Book free consultation